HUP0300745A2 - Kodon-optimalizált papillómavírus szekvenciák - Google Patents

Kodon-optimalizált papillómavírus szekvenciák

Info

Publication number
HUP0300745A2
HUP0300745A2 HU0300745A HUP0300745A HUP0300745A2 HU P0300745 A2 HUP0300745 A2 HU P0300745A2 HU 0300745 A HU0300745 A HU 0300745A HU P0300745 A HUP0300745 A HU P0300745A HU P0300745 A2 HUP0300745 A2 HU P0300745A2
Authority
HU
Hungary
Prior art keywords
codon
optimized
papilloma virus
virus sequences
subject
Prior art date
Application number
HU0300745A
Other languages
English (en)
Inventor
Peter Ertl
Gerald W. Gough
Vanita Parmar
Christopher Jeffrey Alan Ring
Sarah Marina Walcott
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0017990.3A external-priority patent/GB0017990D0/en
Priority claimed from GB0025802A external-priority patent/GB0025802D0/en
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of HUP0300745A2 publication Critical patent/HUP0300745A2/hu
Publication of HUP0300745A3 publication Critical patent/HUP0300745A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

A találmány tárgyát a humán papillómavírus fertőzések, azok tünetei ésaz ehhez kapcsolódó betegségek kezelésében és megelőzésébenhasználható módszerek és készítmények képezik. A találmány tárgyát egypolinukleotid szekvencia képezi, ami egy humán papillómavírus aminosavszekvenciát kódol, és a polinukleotid szekvencia kodonhasznosításimintázata hasonlít az erősen expresszálódó emlős (humán) génekére. Ó
HU0300745A 2000-07-21 2001-07-20 Codon-optimized papilloma virus sequences HUP0300745A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0017990.3A GB0017990D0 (en) 2000-07-21 2000-07-21 Papilloma virus sequences
GB0025802A GB0025802D0 (en) 2000-10-20 2000-10-20 Papilloma virus sequences
PCT/GB2001/003290 WO2002008435A1 (en) 2000-07-21 2001-07-20 Codon-optimized papilloma virus sequences

Publications (2)

Publication Number Publication Date
HUP0300745A2 true HUP0300745A2 (hu) 2003-08-28
HUP0300745A3 HUP0300745A3 (en) 2010-01-28

Family

ID=26244703

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0300745A HUP0300745A3 (en) 2000-07-21 2001-07-20 Codon-optimized papilloma virus sequences

Country Status (22)

Country Link
EP (1) EP1301614B1 (hu)
JP (1) JP2004504057A (hu)
KR (1) KR100874552B1 (hu)
CN (1) CN1262665C (hu)
AT (1) ATE346947T1 (hu)
AU (2) AU2001275695B9 (hu)
BR (1) BR0112637A (hu)
CA (1) CA2416488A1 (hu)
CY (1) CY1106334T1 (hu)
CZ (1) CZ2003180A3 (hu)
DE (1) DE60124918T2 (hu)
DK (1) DK1301614T3 (hu)
ES (1) ES2277605T3 (hu)
HK (1) HK1056195B (hu)
HU (1) HUP0300745A3 (hu)
IL (1) IL154009A0 (hu)
MX (1) MXPA03000554A (hu)
NO (1) NO20030219L (hu)
NZ (1) NZ523683A (hu)
PL (1) PL365385A1 (hu)
PT (1) PT1301614E (hu)
WO (1) WO2002008435A1 (hu)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2842964A1 (de) 2001-06-05 2015-03-04 Curevac GmbH Virtuelles Verfahren zur Ermittlung einer modifzierten mRNA-Sequenz
WO2003018055A1 (en) * 2001-08-23 2003-03-06 Merck & Co., Inc. Vaccine using papilloma virus e proteins delivered by viral vector
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
WO2003068804A2 (en) * 2002-02-14 2003-08-21 Novavax, Inc. Novel insect cell line
GB0222953D0 (en) * 2002-10-03 2002-11-13 Glaxo Group Ltd Novel Compounds
CN100506999C (zh) 2003-03-24 2009-07-01 麦克公司 Hpv31l1在酵母中的优化表达
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
MY140664A (en) 2003-09-29 2010-01-15 Merck Sharp & Dohme Optimized expression of hpv 45 l1 in yeast
MY139500A (en) 2003-11-12 2009-10-30 Merck Sharp & Dohme Optimized expression of hpv 58 l1 in yeast
DK1730175T3 (da) 2004-03-24 2010-08-23 Merck Sharp & Dohme Geoptimaliseerde expressie van HPV 52 L1 in gist
GB0617387D0 (en) * 2006-09-04 2006-10-11 Glaxo Group Ltd Synthetic gene
US8772256B2 (en) * 2006-11-30 2014-07-08 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Codon modified immunogenic compositions and methods of use
GB0700914D0 (en) * 2007-01-18 2007-02-28 Animal Health Inst Polynucleotides and uses thereof
CN101617052A (zh) 2007-01-30 2009-12-30 特兰斯吉恩股份有限公司 用于免疫的乳头瘤病毒e2多肽
BRPI0809600B1 (pt) 2007-03-30 2023-01-24 The Research Foundation Of State University Of New York Vírus atenuado útil para vacinas
GB0710538D0 (en) * 2007-06-01 2007-07-11 Glaxo Group Ltd Vaccine
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3431485B1 (en) 2010-10-01 2020-12-30 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
WO2012135805A2 (en) 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
AU2012318752B2 (en) 2011-10-03 2017-08-31 Modernatx, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
CN104114572A (zh) 2011-12-16 2014-10-22 现代治疗公司 经修饰的核苷、核苷酸和核酸组合物
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
EP2833923A4 (en) 2012-04-02 2016-02-24 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低密度リポタンパク質受容体をコードするポリヌクレオチド
CA2925021A1 (en) 2013-11-01 2015-05-07 Curevac Ag Modified rna with decreased immunostimulatory properties
US11007260B2 (en) 2015-07-21 2021-05-18 Modernatx, Inc. Infectious disease vaccines
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
MA45209A (fr) 2015-10-22 2019-04-17 Modernatx Inc Vaccins contre les maladies sexuellement transmissibles
PE20181529A1 (es) 2015-10-22 2018-09-26 Modernatx Inc Vacunas de acido nucleico para el virus varicela-zoster (vzv)
EP3364950A4 (en) 2015-10-22 2019-10-23 ModernaTX, Inc. VACCINES AGAINST TROPICAL DISEASES
CA3003678A1 (en) 2015-10-30 2017-05-04 Children's National Medical Center Generating hpv antigen-specific t cells from a naive t cell population
US10925958B2 (en) 2016-11-11 2021-02-23 Modernatx, Inc. Influenza vaccine
EP3551193A4 (en) 2016-12-08 2020-08-19 Modernatx, Inc. NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUSES
US11045540B2 (en) 2017-03-15 2021-06-29 Modernatx, Inc. Varicella zoster virus (VZV) vaccine
MA47787A (fr) 2017-03-15 2020-01-22 Modernatx Inc Vaccin contre le virus respiratoire syncytial
US11752206B2 (en) 2017-03-15 2023-09-12 Modernatx, Inc. Herpes simplex virus vaccine
US11576961B2 (en) 2017-03-15 2023-02-14 Modernatx, Inc. Broad spectrum influenza virus vaccine
WO2019055807A1 (en) 2017-09-14 2019-03-21 Modernatx, Inc. RNA VACCINES AGAINST ZIKA VIRUS
EP3746090A4 (en) 2018-01-29 2021-11-17 ModernaTX, Inc. RSV RNA Vaccines
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464936A (en) * 1990-12-21 1995-11-07 Cetus Oncology Corporation Compositions for identification of papillomavirus replication inhibitors
DE4123760C2 (de) * 1991-07-18 2000-01-20 Dade Behring Marburg Gmbh Seroreaktive Bereiche auf den HPV 16 Proteinen E1 und E2
AU743616B2 (en) * 1997-02-07 2002-01-31 Merck & Co., Inc. Synthetic HIV gag genes
AU766403C (en) * 1998-09-04 2004-05-27 Aventis Pasteur Limited Treatment of cervical cancer
ATE284898T1 (de) * 1999-08-25 2005-01-15 Merck & Co Inc Synthetische papillomavirus gene, welche für expression in menschlichen zellen optimiert sind

Also Published As

Publication number Publication date
DE60124918T2 (de) 2007-08-02
PL365385A1 (en) 2005-01-10
CN1462309A (zh) 2003-12-17
NO20030219L (no) 2003-03-20
PT1301614E (pt) 2007-02-28
CA2416488A1 (en) 2002-01-31
MXPA03000554A (es) 2004-12-13
HK1056195A1 (en) 2004-02-06
KR20030074586A (ko) 2003-09-19
NO20030219D0 (no) 2003-01-16
HK1056195B (zh) 2007-06-22
EP1301614B1 (en) 2006-11-29
NZ523683A (en) 2004-08-27
AU7569501A (en) 2002-02-05
EP1301614A1 (en) 2003-04-16
ATE346947T1 (de) 2006-12-15
ES2277605T3 (es) 2007-07-16
KR100874552B1 (ko) 2008-12-16
BR0112637A (pt) 2003-06-10
IL154009A0 (en) 2003-07-31
CZ2003180A3 (cs) 2003-08-13
JP2004504057A (ja) 2004-02-12
WO2002008435A1 (en) 2002-01-31
WO2002008435A8 (en) 2002-04-04
DK1301614T3 (da) 2007-04-02
DE60124918D1 (de) 2007-01-11
CY1106334T1 (el) 2011-10-12
AU2001275695B9 (en) 2005-05-26
AU2001275695B2 (en) 2005-01-27
CN1262665C (zh) 2006-07-05
HUP0300745A3 (en) 2010-01-28

Similar Documents

Publication Publication Date Title
HUP0300745A2 (hu) Kodon-optimalizált papillómavírus szekvenciák
HUP0400685A2 (hu) Módosított Vacciniavírus Ankara-variáns
HUP0401124A2 (hu) VII koagulációs faktor származékok
HUP0302965A2 (hu) Vakcina
HUP0303996A2 (hu) Vakcinakészítmények
HUP0402162A2 (hu) A humán angiopoietin-2 specifikus kötőanyagai
HUP0301452A2 (hu) Fotokemoterápiás szert és mukoadhéziós szert tartalmazó gyógyszerkészítmény és alkalmazása
HUP0300814A2 (hu) Peptidszelekciós módszer
HUP0303130A2 (hu) A VII-es faktor és a VIII-as faktor polipeptidek kombinált alkalmazása és ezeket tartalmazó gyógyszerkészítmények
HUP0003386A2 (hu) CRF antagonisták alkalmazása depresszió, kardiovaszkuláris betegségek kezelésére szolgáló gyógyszerkészítmények előállítására
HUP0100526A2 (hu) HPV-antigén elleni készítmények, alkalmazásaik és eljárások előállításukra
DE69330988D1 (de) Peptide des menschlichen papillomavirus zur verwendung in zusammensetzungen, die eine menschliche t-zellreaktion induzieren
WO2021000968A3 (zh) 一种用于预防SARS-CoV-2感染的腺病毒载体疫苗
TW200502246A (en) Vaccine
HUP0500039A2 (hu) Vakcina és eljárás mozgatóneuron-betegségek kezelésére
HUP0303431A2 (hu) PRRS vírus élő legyengített törzsei
HUP0302481A2 (hu) Virulencia gének, fehérjék és alkalmazásuk
DE69736276D1 (de) Menschliche dnase resistent gegen actininhibitoren
WO2003022202A3 (en) Compositions and methods for treatment of cancer
HUP0302233A2 (hu) Virális betegségek kezelésére IL-18-cal és IL-18 kombinációkkal
WO2005002511A3 (en) Recombinant antibodies and compositions and methods for making and using the same
HUP0300997A2 (hu) A MIA-fehérje alkalmazása immunterápiában
HUP0300787A2 (hu) Új interferon a sclerosis multiplex kezelésére
HUP0200162A2 (hu) Haemophilus somnus transzferrin-kötő fehérjék klónozása és expresszálása
HUP0300813A2 (hu) Gének, fehérjék és alkalmazásuk

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished